BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21667134)

  • 1. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer.
    Satoh S; Okabe H; Teramukai S; Hasegawa S; Ozaki N; Ueda S; Tsuji A; Sakabayashi S; Fukushima M; Sakai Y
    Gastric Cancer; 2012 Jan; 15(1):61-9. PubMed ID: 21667134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
    Yamaguchi T; Takashima A; Nagashima K; Makuuchi R; Aizawa M; Ohashi M; Tashiro K; Yamada T; Kinoshita T; Hata H; Kawachi Y; Kawabata R; Tsuji T; Hihara J; Sakamoto T; Fukagawa T; Katai H; Higuchi K; Boku N
    Ann Surg Oncol; 2020 Jan; 27(1):284-292. PubMed ID: 31535301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
    Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
    Kanazawa Y; Kato S; Fujita I; Onodera H; Uchida E
    J Nippon Med Sch; 2013; 80(5):378-83. PubMed ID: 24189356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
    Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
    Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis.
    Katayama H; Tsuburaya A; Mizusawa J; Nakamura K; Katai H; Imamura H; Nashimoto A; Fukushima N; Sano T; Sasako M
    Gastric Cancer; 2019 Nov; 22(6):1301-1307. PubMed ID: 31264058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
    Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
    J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
    Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
    Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
    Emoto S; Kitayama J; Ishigami H; Yamaguchi H; Watanabe T
    Ann Surg Oncol; 2015 Mar; 22(3):780-6. PubMed ID: 25216603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
    World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
    Iwasaki Y; Sasako M; Yamamoto S; Nakamura K; Sano T; Katai H; Tsujinaka T; Nashimoto A; Fukushima N; Tsuburaya A;
    J Surg Oncol; 2013 Jun; 107(7):741-5. PubMed ID: 23400787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
    Yamashita K; Ushiku H; Katada N; Hosoda K; Moriya H; Mieno H; Kikuchi S; Hoshi K; Watanabe M
    Eur J Surg Oncol; 2015 Oct; 41(10):1324-32. PubMed ID: 26251341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study).
    Yoshikawa T; Omura K; Kobayashi O; Nashimoto A; Takabayashi A; Yamada T; Yamaue H; Fujii M; Yamaguchi T; Nakajima T
    Eur J Surg Oncol; 2010 Jun; 36(6):546-51. PubMed ID: 20541062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
    Mieno H; Yamashita K; Hosoda K; Moriya H; Higuchi K; Azuma M; Komori S; Yoshida T; Tanabe S; Koizumi W; Katada N; Watanabe M
    Surg Today; 2017 Oct; 47(10):1249-1258. PubMed ID: 28365892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
    Yoshikawa T; Morita S; Tanabe K; Nishikawa K; Ito Y; Matsui T; Fujitani K; Kimura Y; Fujita J; Aoyama T; Hayashi T; Cho H; Tsuburaya A; Miyashita Y; Sakamoto J
    Eur J Cancer; 2016 Jul; 62():103-11. PubMed ID: 27244537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
    Kodera Y; Ito S; Mochizuki Y; Kondo K; Koshikawa K; Suzuki N; Kojima H; Kojima T; Matsui T; Takase T; Tsuboi K; Fujiwara M; Nakao A;
    Eur J Surg Oncol; 2009 Nov; 35(11):1158-63. PubMed ID: 19328643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
    BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.